Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Indoco Remedies Ltd. Share Price
Day's Range
Day's Range
Low
₹229.05
High
₹239.00
Price Summary
| Previous Close | ₹234.99 |
|---|---|
| Day's Range | ₹229.05 - ₹239.00 |
| Open | ₹230.81 |
| 52 Week Range | ₹162.19 - ₹349.80 |
| Volume | 1,27,773 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 300.29 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.08 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -10.31 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 2.32 |
| PAT Margin (%) | -4.68 |
| Face Value (₹) | 2.00 |
| ROCE(%) | -0.43 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 15181.9 | 3472.5 |
| Expenses | N/A | N/A |
| PBT | -73.7 | -309.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -87.3 | -262.4 |
About Indoco Remedies Ltd.
| Founded | 1947 |
|---|---|
| Managing Director | Aditi Panandikar |
| NSE Symbol | INDOCO |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,40,793.82 | 1,838.35 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,956.35 | 6,752.80 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,819.64 | 4,421.70 | 3,140.10 - 3,140.10 |
| Apollo Hospitals Enterprise Ltd. | 1,22,170.95 | 8,516.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,09,370.14 | 1,353.85 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,07,757.60 | 1,070.60 | 835.50 - 835.50 |
| Lupin Ltd. | 1,07,536.52 | 2,347.65 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,06,672.39 | 1,092.00 | 903.00 - 903.00 |
| Dr. Reddy's Laboratories Ltd. | 1,06,133.20 | 1,271.55 | 1,148.40 - 1,148.40 |
| Mankind Pharma Ltd. | 99,835.58 | 2,417.35 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Indoco Remedies informs about transcript of conference call
Pursuant to the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Indoco Remedies has informed that it enclosed the transcript of Earnings Conference Call held on 07th May, 2026 at 03:30 pm (IST) in respect of Audited Standalone and Consolidated Financial Results for the Quarter and Year Ended 31st March, 2026. The Earnings Conference Call concluded at 04:23 pm (IST) on 07th May, 2026.
Brooks Laboratories informs about partial sale of equity shares
Brooks Laboratories has informed that the Company at its board meeting held today, 19th June 2026 has approved sale of 51,220 equity shares held by the Company in Brooks Steriscience to Steriscience Specialities.
The above information is a part of company’s filings submitted to BSE.
Aurobindo Pharma informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: The United States Food and Drug Administration (US FDA) conducted a PAI at Eugia Steriles (a 100% subsidiary of Eugia Pharma Specialities and a stepdown subsidiary of the Company), situated at Parawada Mandal, Anakapalli District, Andhra Pradesh, from June 10, 2026, to June 19, 2026. The inspection concluded with 5 observations and will be responded to within the stipulated time. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe. The company will keep the stock exchanges informed if there is any further information relating to the above in the future. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as ‘Annexure’.
The above information is a part of company’s filings submitted to BSE.
Source Natural Foods and Herbal Supplements informs about incorporation of WOS
Alembic Pharmaceuticals informs about press release
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Indoco Remedies Ltd. is ₹234.99 as of 2026-06-19.
The market capitalisation of Indoco Remedies Ltd. is ₹2,174.67 as of 2026-06-19.
The 1-year return of Indoco Remedies Ltd. is 0.00% as of 2026-06-19.
The P/E ratio of Indoco Remedies Ltd. is 0.00 as of 2026-06-20.
The 52-week high and low of Indoco Remedies Ltd. are ₹349.80 and ₹162.19, respectively, as of 2026-06-19.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
